CBD and postpartum depression and baby blues: what does science say about safety

Postpartum motherhood is a time of profound hormonal, emotional, and social changes. Baby blues affects up to 80% mothers in the first weeks, and postpartum depression affects 10–15% women, often requiring clinical intervention. Online, a growing number of posts and recommendations suggesting CBD as a natural support during this difficult time. This article approaches the topic differently: with a particularly strong safety framework. The question "does CBD work for postpartum depression" is secondary to the question "is CBD safe for breastfeeding mothers and their babies?" And this question has a clear, science-based answer.

KEY INFORMATION
• CBD passes into breast milk — Bertrand et al. (Pediatrics, 2018) detected it in milk samples for at least 6 days after exposure.
• ACOG, AAP, and WHO advise against the use of CBD (and all cannabinoids) while breastfeeding due to a lack of safety data for infants.
• Postpartum depression is a condition requiring clinical interventions (CBT, SSRIs) — not supplements.
• Baby blues (up to 2 weeks postpartum) usually resolve on their own; if symptoms persist beyond 2 weeks — psychiatric consultation, not CBD.

What is baby blues, and what is postpartum depression?

The distinction between baby blues and postpartum depression (PPD) is crucial for practical reasons — it determines the appropriate therapeutic response. Baby blues is a physiological, transient reaction occurring in 50–80% of mothers within 2–3 days after childbirth and typically resolving before the end of the second week. It manifests as tearfulness, irritability, mood swings, and anxiety — resulting from a sharp drop in estrogen and progesterone after childbirth. It does not require treatment — but does require emotional support, rest, and time.

Postpartum depression (PPD) is a clinical state that meets the criteria for a depressive episode: persistent sadness lasting more than 2 weeks, loss of joy in motherhood (anhedonia), sleep disturbances unrelated to the baby's needs, obsessive thoughts (e.g., about harming the baby), difficulties with caregiving and bonding. According to data WHO (2023) PPD affects 10–15% of mothers postpartum and is one of the most common complications of the postpartum period. In Poland, this means tens of thousands of women each year.

PPD doesn't resolve on its own and requires clinical interventions—psychotherapy, pharmacotherapy, or both. Delaying seeking help, hoping it will "go away on its own" or that "CBD will help," can delay treatment and worsen the condition. This is the most important message of this article.

What does science say about CBD and breastfeeding?

Study Bertrand et al. published in Pediatrics (2018) This is a key reference point in the discussion about CBD and lactation. The authors examined breast milk samples from 50 breastfeeding women who reported using marijuana (containing both THC and CBD). CBD was detectable in the breast milk samples for at least 6 days after the last exposure—meaning the infant is exposed to cannabidiol even if the mother didn't use CBD that day. THC was detected even after a longer period of time—up to 6 weeks with regular prior use.

Why does CBD readily pass into milk? CBD is a highly lipophilic molecule — and breast milk contains 3–5% fat, which serves as an ideal carrier for lipophilic substances. A woman's milk is biologically enriched with fat precisely to provide energy to the developing brain of the infant — which also concentrates CBD.

A key data gap: the study by Bertrand et al. confirmed that CBD passes into milk — but did not assess the effects of this exposure on the infant. We do not have clinical data showing how specific amounts of CBD in milk affect neurodevelopment, sleep, feeding, or other parameters of the infant. This gap in knowledge is precisely the main reason why ACOG, AAP, and WHO recommend avoiding all cannabinoids while breastfeeding.

The endocannabinoid system of infants – why exposure matters

One reason the WHO and ACOG use a precautionary approach with CBD during lactation is the active endocannabinoid system (ECS) in infants. The ECS isn't "just a receptor"—it performs crucial regulatory functions in the developing brain, orchestrating neuronal proliferation, migration, synapse formation, and myelination. Endocannabinoids (anandamide, 2-AG) are actively present in the infant brain.

External cannabinoids — including CBD — can modulate ECS signaling in infants. We do not know whether this modulation is neutral, beneficial, or harmful to the developing brain. Animal studies suggest that disrupting ECS signaling during critical periods of neurodevelopment may have long-term behavioral consequences — but these findings cannot be directly translated to humans. The lack of data does not mean a lack of risk — and that is precisely why the precautionary principle makes particular sense here.

Breast milk naturally contains endocannabinoids — anandamide is detected in human milk and likely serves regulatory functions for the infant. But these are different cannabinoids than externally supplied CBD: endogenous ones are produced in controlled amounts and metabolized locally. Externally supplied CBD enters milk in uncontrolled amounts and may act on different receptors than endogenous cannabinoids.

Effective methods for treating postpartum depression – what has evidence

Postpartum depression is a well-researched, treatable condition — and we have solid data on methods that work. Not CBD, but specific therapies with evidence ranking.

Psychotherapy: Cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT) have the highest level of evidence (Grade A) in treating mild to moderate PPD. Randomized clinical trials have shown effectiveness comparable to pharmacotherapy with no side effects. In Poland, access to CBT is available through the National Health Fund (usually long waiting times) or private psychological practices.

Pharmacotherapy: Sertraline (Zoloft) and escitalopram (Lexapro) are considered first-line medications for PPD in breastfeeding women — they have a long track record of safety during lactation, are well-studied, and have a favorable profile for transfer to breast milk. A psychiatrist or gynecologist with experience in perinatology can appropriately select the medication and dosage. Breastfeeding is not a contraindication for treating PPD.

Social support and support groups: Mothers with mild PPD benefit significantly from support groups (online and in-person), regular contact with loved ones, and structured peer support. The Tato.Net Foundation, Postpartum Support International (Poland Branch), and the Polish Society of Gynecologists and Obstetricians have resources for mothers with PPD symptoms.

Clinically significant observation: In practice, many women with PPD symptoms turn to CBD for understandable reasons—it's readily available, "natural," and non-stigmatizing, unlike psychiatry, which is still surrounded by social taboos. This is an important behavioral aspect: CBD can be a "gateway" to seeking support, but it shouldn't be the end goal. If you're considering CBD for PPD, it's a sign you need support, and that support is available in the form of proven therapies. Instead of CBD, call a psychiatrist or psychologist.

Is there any situation where CBD postpartum can be considered?

Yes — but with precise caveats. Women who have finished breastfeeding and are no longer lactating have a different risk profile than breastfeeding women. The lack of exposure to the infant through milk eliminates the main source of uncertainty. In such a scenario, a woman with mild PPD or chronic postpartum stress, after finishing breastfeeding, may — after consulting with a psychiatrist or gynecologist — consider CBD as one of the support tools alongside psychotherapy.

Even then: CBD is not a first or second-line therapy for PPD. It is a potential supplement after breastfeeding is completed, in cases of mild symptom severity and under medical supervision. It is not a substitute for CBT therapy, antidepressants, or psychiatric support. If you have any thoughts of self-harm or harming your child — contact a doctor immediately or call emergency numbers (112, Women's Helpline 116 123).

More about the safety of CBD during pregnancy and lactation in the article: CBD and pregnancy and breastfeeding.

CBD and the endocannabinoid system in depression – what does neurobiology say?

Part of the interest in CBD in the context of postpartum depression stems from neurobiologically justified premises. The endocannabinoid system (ECS) is involved in mood regulation, stress reactivity, and neuroplasticity — which has biological significance in the pathophysiology of depression. Studies on animal models show that disruption of endocannabinoid signaling exacerbates depressive behaviors, and its enhancement by CBD exerts an antidepressant effect.

Particularly interesting in the context of PPD are the data on CBD and the HPA axis (hypothalamic-pituitary-adrenal axis). PPD is partially modulated by dysregulation of this axis — excessive cortisol secretion, weakened glucocorticoid receptor response. CBD modulates the HPA axis through 5-HT1A receptors, which could theoretically justify its use in treating PPD. Shannon et al. (Permanente Journal, 2019) described a reduction in anxiety in 79% of patients using CBD — but this was not a postpartum mother population, and results from the general population do not automatically translate to the specific postpartum breastfeeding situation.

In short: the biological premises for CBD in depression are real and interesting. But the mere biological justification does not translate into clinical recommendations — there is a lack of studies on the appropriate population, in the right context, considering the safety of lactation. It is this gap, rather than a denial of CBD as a substance, that underlies the caution of medical organizations.

Preventable risk factors for PPD

Postpartum depression rarely appears without warning — most cases have recognizable risk factors that can be addressed during pregnancy or shortly after childbirth. Knowledge of these factors can be more valuable than seeking supplements.

The main risk factors for PPD include: a previous episode of depression or anxiety disorders (the strongest predictor, with a three- to four-fold increased risk), poor partner and social support, difficult socioeconomic circumstances, complications during childbirth, infant colic or breastfeeding difficulties (which translates into chronic sleep deprivation for the mother), and a lack of a plan for "who will help" in the first weeks. Women with a history of depression should receive active screening and a preliminary plan from a psychiatrist during pregnancy—without waiting for symptoms after delivery. Many maternity hospitals in Poland offer such preventive programs.

How to talk to your doctor about CBD for postpartum symptoms?

If you have already decided to talk to your doctor, it is worth knowing that more and more gynecologists and perinatal psychiatrists are familiar with CBD and are prepared for an informed discussion. You do not need to hide this — transparency will allow the doctor to assess safety and potential interactions with other medications.

Many patients are afraid to tell their doctor about their interest in CBD — they fear judgment or disapproval. Meanwhile, an open conversation with a gynecologist or perinatal psychiatrist is exactly what you need to make a safe decision. The doctor can assess the specific situation — the severity of symptoms, current pharmacotherapy, stage of lactation, overall health — and tell you whether and when CBD may be considered.

Useful questions to ask your doctor: "Is CBD safe with my current medications?" (crucial for SSRIs—both due to metabolic interactions via CYP and the potential additive serotonin effect), "Can I use CBD after breastfeeding?", "Is it an alternative to SSRIs for mild PPD if I want to avoid medication?" CBT therapists and perinatal psychiatrists are the specialists best equipped to manage women with PPD. In Poland, you can find specialists through the Polish Psychiatric Association and the Center for Community Psychiatry.

Frequently Asked Questions

Is CBD safe postpartum?

When breastfeeding — there is not enough safety data. Bertrand et al. (Pediatrics, 2018) confirmed that CBD passes into breast milk for at least 6 days. ACOG, AAP, and WHO advise against the use of CBD during lactation due to the principle of caution and lack of safety data for infants.

Does CBD pass into breast milk?

Yes — CBD is lipophilic and passes into the fat of breast milk. A study Bertrand et al. (Pediatrics, 2018) showed detectable CBD in milk samples for at least 6 days after the last exposure. Therefore, the infant is exposed even if the mother "did not take CBD today.".

How to treat postpartum depression without CBD?

PPD requires clinical interventions: CBT (cognitive-behavioral therapy), IPT (interpersonal therapy), SSRI pharmacotherapy (sertraline, escitalopram — safe during breastfeeding according to psychiatrists), and social support. For mild PPD, CBT is the first-line therapy. A psychiatric or psychological consultation is the appropriate path.

Can CBD cause problems in infants?

There is a lack of clinical data defining the effects of infant exposure to CBD through breast milk. The endocannabinoid system in infants is active and developmentally significant — external cannabinoids could theoretically modulate it. The principle of caution: avoid exposing the infant to CBD and THC.

What is baby blues and how to distinguish it from postpartum depression?

Baby blues is a physiological hormonal response in 50–80% of mothers, usually resolving within 2 weeks after childbirth — it does not require treatment but does require emotional support and rest. Postpartum depression lasts longer than 2 weeks, has deeper symptoms (anhedonia, difficulties with care, obsessive thoughts), and affects 10–15% of mothers (WHO, 2023) — requires psychiatric or psychological intervention, not CBD supplements. If you have any thoughts of self-harm — contact a doctor immediately or call 116 123.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04